Universität zu Köln

Goede, Valentin, Cramer, Paula, Busch, Raymonde, Bergmann, Manuela, Stauch, Martina, Hopfinger, Georg, Stilgenbauer, Stephan, Doehner, Hartmut, Westermann, Anne, Wendtner, Clemens M., Eichhorst, Barbara and Hallek, Michael (2014). Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica, 99 (6). S. 1095 - 1101. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Full text not available from this repository.

Abstract

This study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic Leukemia Study Group on first-line treatment with fludarabine plus cyclophosphamide, fludarabine, or chlorambucil. Patients with two or more comorbidities and patients with less than two comorbidities differed in overall survival (71.7 versus 90.2 months; P<0.001) and progression-free survival (21.0 versus 31.5 months; P<0.01). After adjustment for other prognostic factors and treatment, comorbidity maintained its independent prognostic value in a multivariate Cox regression analysis. Chronic lymphocytic leukemia was the major cause of death in patients with two or more comorbidities. Disease control in patients with two or more comorbidities was better with fludarabine plus cyclophosphamide than with fludarabine treatment, but not with fludarabine compared to chlorambucil treatment. These results give insight into interactions between comorbidity and therapy of chronic lymphocytic leukemia and suggest that durable control of the hematologic disease is most critical to improve overall outcome of patients with increased comorbidity. The registration numbers of the trials reported are NCT00276848 and NCT00262795.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Goede, Valentin UNSPECIFIED UNSPECIFIED UNSPECIFIED Cramer, Paula UNSPECIFIED UNSPECIFIED UNSPECIFIED Busch, Raymonde UNSPECIFIED UNSPECIFIED UNSPECIFIED Bergmann, Manuela UNSPECIFIED UNSPECIFIED UNSPECIFIED Stauch, Martina UNSPECIFIED UNSPECIFIED UNSPECIFIED Hopfinger, Georg UNSPECIFIED UNSPECIFIED UNSPECIFIED Stilgenbauer, Stephan UNSPECIFIED UNSPECIFIED UNSPECIFIED Doehner, Hartmut UNSPECIFIED UNSPECIFIED UNSPECIFIED Westermann, Anne UNSPECIFIED UNSPECIFIED UNSPECIFIED Wendtner, Clemens M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-437468
DOI:	10.3324/haematol.2013.096792
Journal or Publication Title:	Haematologica
Volume:	99
Number:	6
Page Range:	S. 1095 - 1101
Date:	2014
Publisher:	FERRATA STORTI FOUNDATION
Place of Publication:	PAVIA
ISSN:	0390-6078
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROGNOSTIC IMPACT; RITUXIMAB REGIMEN; 1ST-LINE THERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; CANCER; POPULATION; VALIDATION; GUIDELINES; DIAGNOSIS Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43746